Diagnosing Lyme disease and associated co-infections has historically been complex, with conventional ELISA and blot methods offering limited sensitivity. Vibrant's Lyme and co-infection microarray technology provides a more refined diagnosis, overcoming the limitations of these traditional approaches.
Traditional methods for diagnosing Lyme disease, such as ELISA and Western blots, are limited by their single-pathogen detection capability, leading to multiple tests for comprehensive diagnosis. Additionally, these methods grapple with inconsistent sensitivity and subjective result interpretation.1
Our Lyme and co-infections protein microarray technology addresses these issues by enabling simultaneous testing of multiple antigens, streamlining the diagnostic process with enhanced accuracy. This approach offers detailed insights into a patient’s condition in one assay, featuring high reproducibility and sensitivity.
Learn more about our technology.
Our microarray's clinical validation has yielded impressive results: a study published in Nature Scientific Reports demonstrated sensitivity and specificity of 100% and 97%2, respectively. These outcomes represent a leap in diagnostic assay capability and underscore the precision of our proprietary technology.
Our recent white paper outlines the methodology, development, and comprehensive clinical validation of our microarray platform, contrasting it with traditional diagnostic methods. It serves as an exhaustive resource for medical professionals seeking detailed information on advancements in the diagnosis of tickborne diseases.
Download the white paper and see how we’re reshaping the landscape of infectious disease diagnostics.
References:
1. Jayaraman, V., Krishna, K., Yang, Y. et al. An ultra-high-density protein microarray for high throughput single-tier serological detection of Lyme disease. Sci Rep 10, 18085 (2020). https://doi.org/10.1038/s41598-020-75036-2
2. Hari Krishnamurthy, Vasanth Jayaraman, Karthik Krishna et al. A customizable multiplex protein microarray for antibody testing and its application for tick-borne and other infectious diseases., 16 October 2023, PREPRINT (Version 2) available at Research Square. https://doi.org/10.21203/rs.3.rs-3417198/v2